Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study
Glutamate dysregulation may be involved in the neuropathology of schizophrenia. Memantine, a drug approved by the FDA for the treatment of moderate to severe Alzheimer's disease, acts as a partial uncompetitive NMDA receptor antagonist. The aim of this study was to examine the efficacy of mema...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Tehran University of Medical Sciences
2016-12-01
|
Series: | Acta Medica Iranica |
Subjects: | |
Online Access: | https://acta.tums.ac.ir/index.php/acta/article/view/5105 |
id |
doaj-2ecc21e6a526423c9fd30312e17f4c6e |
---|---|
record_format |
Article |
spelling |
doaj-2ecc21e6a526423c9fd30312e17f4c6e2020-11-25T03:43:00ZengTehran University of Medical SciencesActa Medica Iranica0044-60251735-96942016-12-0154115090Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled StudyAhmad Fakhri0Sirous Pakseresht1Mohammad Reza Haghdoost2Nasihat Hekmatkhah3Maria Torkashvand4Behnam Ghorbanzadeh5Department of Psychiatry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.Department of Psychiatry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.Department of Psychiatry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.Department of Psychiatry, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.Department of Internal Medicine, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.Department of Pharmacology, School of Medicine, Dezful University of Medical Sciences, Dezful, Iran. Glutamate dysregulation may be involved in the neuropathology of schizophrenia. Memantine, a drug approved by the FDA for the treatment of moderate to severe Alzheimer's disease, acts as a partial uncompetitive NMDA receptor antagonist. The aim of this study was to examine the efficacy of memantine as an adjunctive treatment to olanzapine in patients with schizophrenia. In this double-blind, placebo-controlled studies, patients with schizophrenia according to DSM-IV clinical criteria were selected. Patients were randomly assigned to receive either memantine (week 1:10 mg/day; weeks 2-6:20 mg/day) plus olanzapine (15-20 mg/day) or olanzapine plus placebo. At baseline, no statistically significant difference regarding the mean total PANSS scores between treatment groups was found. Results showed that memantine significantly improved the positive and negative PANSS score in patients maintained on olanzapine after six weeks compared to olanzapine alone (P<0.001). Furthermore, female patients showed significantly better response than males, especially in positive PANSS score. No significant changes in extrapyramidal symptoms were observed.These findings indicate that olanzapine efficacy might be augmented with memantine. Furthermore, this effect is more remarkable in female patients with schizophrenia. https://acta.tums.ac.ir/index.php/acta/article/view/5105MemantineSchizophreniaCombination therapyGenderNMDA receptors |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ahmad Fakhri Sirous Pakseresht Mohammad Reza Haghdoost Nasihat Hekmatkhah Maria Torkashvand Behnam Ghorbanzadeh |
spellingShingle |
Ahmad Fakhri Sirous Pakseresht Mohammad Reza Haghdoost Nasihat Hekmatkhah Maria Torkashvand Behnam Ghorbanzadeh Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study Acta Medica Iranica Memantine Schizophrenia Combination therapy Gender NMDA receptors |
author_facet |
Ahmad Fakhri Sirous Pakseresht Mohammad Reza Haghdoost Nasihat Hekmatkhah Maria Torkashvand Behnam Ghorbanzadeh |
author_sort |
Ahmad Fakhri |
title |
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study |
title_short |
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study |
title_full |
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study |
title_fullStr |
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study |
title_full_unstemmed |
Memantine Enhances the Effect of Olanzapine in Patients With Schizophrenia: A Randomized, Placebo-Controlled Study |
title_sort |
memantine enhances the effect of olanzapine in patients with schizophrenia: a randomized, placebo-controlled study |
publisher |
Tehran University of Medical Sciences |
series |
Acta Medica Iranica |
issn |
0044-6025 1735-9694 |
publishDate |
2016-12-01 |
description |
Glutamate dysregulation may be involved in the neuropathology of schizophrenia. Memantine, a drug approved by the FDA for the treatment of moderate to severe Alzheimer's disease, acts as a partial uncompetitive NMDA receptor antagonist. The aim of this study was to examine the efficacy of memantine as an adjunctive treatment to olanzapine in patients with schizophrenia. In this double-blind, placebo-controlled studies, patients with schizophrenia according to DSM-IV clinical criteria were selected. Patients were randomly assigned to receive either memantine (week 1:10 mg/day; weeks 2-6:20 mg/day) plus olanzapine (15-20 mg/day) or olanzapine plus placebo. At baseline, no statistically significant difference regarding the mean total PANSS scores between treatment groups was found. Results showed that memantine significantly improved the positive and negative PANSS score in patients maintained on olanzapine after six weeks compared to olanzapine alone (P<0.001). Furthermore, female patients showed significantly better response than males, especially in positive PANSS score. No significant changes in extrapyramidal symptoms were observed.These findings indicate that olanzapine efficacy might be augmented with memantine. Furthermore, this effect is more remarkable in female patients with schizophrenia.
|
topic |
Memantine Schizophrenia Combination therapy Gender NMDA receptors |
url |
https://acta.tums.ac.ir/index.php/acta/article/view/5105 |
work_keys_str_mv |
AT ahmadfakhri memantineenhancestheeffectofolanzapineinpatientswithschizophreniaarandomizedplacebocontrolledstudy AT sirouspakseresht memantineenhancestheeffectofolanzapineinpatientswithschizophreniaarandomizedplacebocontrolledstudy AT mohammadrezahaghdoost memantineenhancestheeffectofolanzapineinpatientswithschizophreniaarandomizedplacebocontrolledstudy AT nasihathekmatkhah memantineenhancestheeffectofolanzapineinpatientswithschizophreniaarandomizedplacebocontrolledstudy AT mariatorkashvand memantineenhancestheeffectofolanzapineinpatientswithschizophreniaarandomizedplacebocontrolledstudy AT behnamghorbanzadeh memantineenhancestheeffectofolanzapineinpatientswithschizophreniaarandomizedplacebocontrolledstudy |
_version_ |
1724522033377705984 |